Therapy Areas: Central Nervous System
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
5 June 2025 - US pharmaceutical company Mycovia Pharmaceuticals Inc announced on Wednesday that the first participant has been enrolled in an investigator-initiated clinical trial evaluating otesecona...
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
29 May 2025 - Clinical stage biopharmaceutical company Estrella Immunopharma Inc (NASDAQ:ESLA) reported on Thursday that the first patient has been dosed in the second cohort of its Phase I/II STARLIG...
Dizal to present promising data in CLL, DLBCL and EGFR-Mutant NSCLC at ASCO 2025
26 May 2025 - Biopharmaceutical company Dizal Pharmaceutical (SSE: 688192) announced on Monday that it will showcase new clinical data for its investigational therapies DZD8586 and DZD6008 at the 2025...
Alar Pharmaceuticals reports first patient dosed in study of extended-release ketamine injection in treatment-resistant depression
15 May 2025 - Alar Pharmaceuticals Inc (TPEx:6785), a Chinese clinical-stage pharmaceutical company developing long-acting injectables to treat central nervous system (CNS) disorders, announced on Wed...
EXACT Therapeutics secures UK patent for non-invasive brain drug delivery technology
14 May 2025 - Clinical-stage precision medicine company EXACT Therapeutics AS (Euronext Growth Oslo:EXTX) announced on Wednesday that it has been granted a patent in the UK covering its proprietary Ac...
Beijing Tide's AT2R antagonist TRD205 advances to Phase II trial in chronic post-surgical neuropathic pain
6 May 2025 - Beijing Tide Pharmaceutical Co Ltd, a subsidiary of China-based Sino Biopharmaceutical Limited (HK:1177), announced on Monday that it has achieved a milestone in developing its first-in-c...